The Latest Cardiac and Vascular News
BOSTON, Sept. 17, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary transcatheter edge-to-edge repair (TEER) therapies. The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR). Results from the CLASP IID […]
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR). “Patients suffering with debilitating symptoms as a result of degenerative mitral regurgitation represent a […]
IRVINE, Calif., Aug. 17, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR). “Delivering the PASCAL Precision system to clinicians in Europe marks another significant step in our partnership with physicians who treat […]
IRVINE, Calif., July 28, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2022. Second Quarter Highlights and Outlook Q2 sales of $1.37 billion were flat versus an elevated prior year; underlying1 sales grew 5 percent Q2 TAVR sales grew 1 percent; underlying 5 percent Q2 EPS was $0.65; adjusted1 EPS […]
IRVINE, Calif., Jan. 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2021. Fourth Quarter Highlights and Outlook 2021 sales grew 19 percent, or 18 percent on an underlying1 basis Q4 sales grew 12 percent to $1.33 billion; underlying 13 percent Q4 TAVR sales grew 12 percent; […]
ONLY HOSPITAL IN COACHELLA VALLEY TO OFFER TAVR RANCHO MIRAGE, Calif., Dec. 16, 2021 /PRNewswire/ — Eisenhower Health is the FIRST hospital in California to be recognized by Edwards Lifesciences for completing its Edwards Benchmark program for the treatment of aortic stenosis in patients undergoing transcatheter aortic valve replacement (TAVR). The standard treatment for aortic […]
IRVINE, Calif., Nov. 6, 2021 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW) announced that results from a clinical trial of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated that favorable patient outcomes were sustained at six months. Results from the TRISCEND study, treating patients with tricuspid regurgitation, were presented during the late-breaking clinical […]
IRVINE, Calif., Nov. 5, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today announced that a cost-effectiveness analysis comparing transcatheter aortic valve replacement (TAVR) to surgery demonstrated that TAVR with SAPIEN 3 is an economically dominant treatment strategy, offering improved outcomes and reduced cost. This analysis from the PARTNER 3 trial was presented during the […]
IRVINE, Calif., Oct. 27, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2021. Third Quarter Highlights and 2021 Outlook Sales grew 15 percent to $1.3 billion; underlying1 sales grew 14 percent TAVR sales grew 15 percent; underlying 14 percent U.S. TAVR sales grew 12 percent; OUS approximately 20 […]
IRVINE, Calif., July 29, 2021 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2021. Second Quarter Highlights and 2021 Outlook Sales rebounded and grew 49 percent to $1.4 billion; underlying1 sales grew 44 percent TAVR sales exceeded expectations and grew 52 percent; underlying sales grew 48 percent EPS […]
